title: Is it possible to cure myeloma without allogeneic transplantation?
abstract: During the last decades, a better understanding of the biology of multiple myeloma (MM) has led to the application of novel treatment strategies for MM patients. The new anti-myeloma regimens produce higher incidence of durable and of better quality responses and they improve overall survival, challenging the dogma of incurable disease, outside the context of allogeneic transplantation. This review presents all these strategies that aim to cure MM, including continuous treatment i.e. induction, consolidation and maintenance, treatment of asymptomatic MM and monitoring minimal residual disease using modern techniques, such as multi-parameter flow cytometry, molecular assays and advanced imaging.
authors: Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece; Greek Myeloma Study Group, Athens, Greece.
authors: Eirini
authors: E
authors: Katodritou
authors: Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
authors: Sofia
authors: S
authors: Papadaki
authors: Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
authors: Pavlina
authors: P
authors: Konstantinidou
authors: Greek Myeloma Study Group, Athens, Greece; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: eterpos@med.uoa.gr.
authors: Evangelos
authors: E
authors: Terpos
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D018365:Neoplasm, Residual / Q000473:pathology; D014184:Transplantation, Homologous
keywords: Allogeneic; Bortezomib; Immunomodulatory drugs; Multiple myeloma; Translantation